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Pulmonary microRNA profiles 
identify involvement of Creb1 and 
Sec14l3 in bronchial epithelial 
changes in allergic asthma
Sabine Bartel1,2,*, Nikola Schulz2,3,*, Francesca Alessandrini4,§, Andrea C. Schamberger2,§, 
Philipp Pagel5, Fabian J. Theis6, Katrin Milger2,7, Elfriede Noessner8, Stephen M. Stick9,10,11,12, 
Anthony Kicic9,10,11,12, Oliver Eickelberg2, Robert J. Freishtat13 & Susanne Krauss-
Etschmann1,2,3,14
Asthma is highly prevalent, but current therapies cannot influence the chronic course of the disease. 
It is thus important to understand underlying early molecular events. In this study, we aimed to 
use microRNAs (miRNAs) - which are critical regulators of signaling cascades - to identify so far 
uncharacterized asthma pathogenesis pathways. Therefore, deregulation of miRNAs was assessed 
in whole lungs from mice with ovalbumin (OVA)-induced allergic airway inflammation (AAI). In silico 
predicted target genes were confirmed in reporter assays and in house-dust-mite (HDM) induced AAI and 
primary human bronchial epithelial cells (NHBE) cultured at the air-liquid interface. We identified and 
validated the transcription factor cAMP-responsive element binding protein (Creb1) and its transcriptional 
co-activators (Crtc1-3) as targets of miR-17, miR-144, and miR-21. Sec14-like 3 (Sec14l3) - a putative target 
of Creb1 - was down-regulated in both asthma models and in NHBE cells upon IL13 treatment, while 
it’s expression correlated with ciliated cell development and decreased along with increasing goblet cell 
metaplasia. Finally, we propose that Creb1/Crtc1-3 and Sec14l3 could be important for early responses 
of the bronchial epithelium to Th2-stimuli. This study shows that miRNA profiles can be used to identify 
novel targets that would be overlooked in mRNA based strategies.
Asthmatic airway disease frequently begins in childhood and affects around 334 million people1. The result-
ing healthcare costs due to medication, hospitalizations, and absence from work are considerable2. Therapeutic 
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options are limited and do not prevent the irreversible changes such as airway remodeling that may occur in 
wheezing preschool children prior to the development of asthma3. Thus, there is a high and unmet clinical need 
for new therapeutic targets and treatment strategies in asthma. A first step to address this need is to identify novel 
pathways that are relevant for asthma pathogenesis.
MicroRNAs (miRNAs) are a class of evolutionary highly conserved, small (20–22 nt) non-coding RNAs that 
post-transcriptionally control gene expression through partial binding to mRNAs. To date, 1,881 human miRNAs 
have been identified (www.mirbase.org), some of which are tissue or cell specific.
Differential expression of miRNAs has been observed in several complex diseases4 including human5–7 and 
experimental asthma8–13. This led to the proposal of miRNAs as therapeutic targets8,9,11,14. However, single miR-
NAs have numerous targets, enabling them to regulate a wide range of genes, with the potential for widespread 
side effects. Additionally, as the expression patterns of many miRNAs differ between disease development and 
disease progression15, targeting them in the tissue of interest and at the most appropriate time is difficult16.
However, single miRNAs can address several key regulatory molecules within a given cellular pathway17. 
This regulatory fine tuning at given molecular sites might result in pronounced and more focused downstream 
effects18–20. Therefore, we asked whether miRNAs, rather than being therapeutic targets, can facilitate the detec-
tion and prioritization of mRNA targets and pathways which might be overlooked by primarily mRNA-based or 
hypothesis driven identification strategies.
Results
Pulmonary miRNA profiling in murine allergic airway inflammation. Female 6–8 week old Balb/c 
mice were intraperitoneally (i.p.) sensitized five times with ovalbumin (OVA) (d7, d14, d28, d42 and d56) (Sigma 
Aldrich, St. Louis, USA) or phosphate buffered saline (PBS) and challenged two times (d70 and d71) with 1% 
OVA aerosol to induce allergic airway inflammation. Changes in pulmonary miRNA expression were analyzed by 
comparing OVA/OVA exposed mice with control mice (PBS/OVA) via locked nucleic acid (LNATM) microarray 
(Exiqon, Vedbaek, Germany). Of the 580 analyzed miRNAs, 55% were expressed in lung tissue and 37 showed 
a statistically significant (cut-off p-value < 10−4) altered expression in OVA-treated animals (Fig. 1a). The high 
number of “primary hits” was validated and confirmed by a PCR-based, quantitative low density array (LDA) 
measuring 518 murine miRNAs (TaqMan, Life Technologies, Carlsbad, USA) (Fig. 1a). From the 37 significantly 
regulated miRNAs (LNATM microarray) six miRNAs were not present on the LDA array, thus could not be meas-
ured, and three miRNAs were below the detection limit of the LDA array. Five miRNAs (miR-290, miR-720, 
Figure 1. Pulmonary miRNA profile and selection of Creb1 as target gene. (a) Fold changes of miRNA 
expression analyzed by Exiqon microarray, TaqMan® microarray and qRT-PCR of lung homogenate of mice 
with OVA-induced allergic airway inflammation and healthy controls on d72 of the treatment protocol (n = 5 
mice per group) with adjusted p-value. n.d.: not detected; - miRNA not available on the array; *minor strand of 
miRNA. (b) List of genes and miRNA-binding sites in their 3′ -UTRs as predicted by five different algorithms 
(miRanda, PicTar, PITA, TargetSpy & TargetScanS). Darker color depicts more binding sites for the same 
miRNA.
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miR-29c, miR-152 and miR-101a) showed inverse expressions, whereas 23 candidates showed comparable 
results (r = 0.62, p ≤ 0.0005; Spearman rho). Quantitative real time PCRs (qRT-PCR) of the six most significantly 
(p ≤ 3.9 × 10–9 – 1.47 × 10−14) dysregulated miRNAs with fold-changes >1.5 further corroborated the results of 
both arrays (Fig. 1a).
Prioritization of targets addressed by differentially expressed miRNAs. We hypothesized that 
a number of different miRNAs, addressing several key molecules in pathways, is driving asthma pathogenesis, 
whereas the magnitude of single miRNA changes per se is less important. Therefore, we included the top 100 
dysregulated miRNAs from the initial LNA microarray for a stringent in silico target prediction. Five different 
algorithms identified a cut-set of 961 potential target genes. We then focused on 11 genes harboring ≥ 4 miRNA 
binding sites (Fig. 1b), since binding of multiple miRNAs to the same target gene can lead to co-regulation and 
stronger effects on target gene expression irrespective of the degree of miRNA changes20. The 3′ UTR of high 
mobility group AT-hook 2 (HMGA2) and trinucleotide repeat containing 6B (TNRC6B) showed the highest 
number of binding sites for single miRNAs (Fig. 1b). However, TNRC6B is an argonaute-associated protein, 
involved in miRNA function itself 21 and was therefore excluded. The interaction between miRNA let-7 and 
HMGA2 has been shown in the context of lung cancer22 and let-7 has been intensively studied in AAI already13. 
Based on the following considerations, we chose the transcription factor Creb1 for further investigation: First, we 
assumed strong control as judged by the high number of miRNA-binding sites (Fig. 1b); second, Creb1 is impor-
tant for the regulation of immune responses23; and third, it is decreased in response to Th2-stimuli24. In total, the 
3′ UTR of Creb1 contains eight predicted binding sites for miR-17 (three sites), miR-144 (one site), miR-22 (two 
sites), and miR-181a (two sites) (Fig. 1b). Furthermore, previous reports suggested a role for Creb1 in asthma and 
COPD25–27.
In vitro validation of predicted miRNA targets. The functional interaction between Creb1 and miR-
17, -144, and -22 was confirmed by luciferase reporter assays (Fig. 2a). Since binding of miR-181a could not be 
proven (Fig. 2a), and miR-22 and could not be confirmed by qRT-PCR, we excluded both miRNAs from further 
analysis. Antagonism of miR-17 or -144 in vitro via transfection of anti-miRs slightly increased CREB1 mRNA 
levels (Fig. 2b).
After phosphorylation, Creb1 has been shown to bind to cAMP-responsive element (CRE) sites in the pro-
moter region of target genes28. Transcriptional activity of Creb1 is enhanced by binding of its co-activators, the 
Creb-regulated transcriptional co-activators (Crtcs)29. We therefore evaluated whether joint down-regulation 
of Crtc proteins and Creb1 by the candidate miRNAs has an additive effect on the transcription of Creb1 down-
stream targets. A less stringent in silico analysis with only two different target prediction tools identified miR-144 
Figure 2. miRNA-regulation of CREB1 in vitro. Transfection of 16-HBE14o− cells with (a) PremiRs 
or scrambled miRNA and a luciferase-vector containing the Creb1 3′ -UTR fused to Renilla luciferase, 
representative of two independent experiments with n = 3 wells. (b,c) AntimiR transfection (n = 3). (b) qRT-
PCR for miRNAs and (c) Creb1. All mean ± SD, *p < 0.05; **p < 0.01, ***p < 0.001 vs. scrambled control.
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and miR-17 (homo sapiens only) binding sites in the 3′ -UTRs of Crtc1 and Crtc3 (Table S1). miRNA-21 was 
included post hoc as it was not only predicted to target Crtc1 and Creb1, but was also the second highest “hit” in 
our array (adj. p-value 6.18 × 10−13). Further, other researchers have suggested that it has a role in allergic airway 
inflammation11,30.
In vitro, Crtc2 levels were significantly reduced by transfection of a miRNA mimic (premiR) of all three 
microRNAs. Crtc3 was reduced by miR-144 and miR-21 over-expression, whereas Crtc1 levels where only 
reduced by miR-21 (Fig. S1a). miR-17 also decreased Crtc2 (Fig. S1a). Antagonism of endogenous miR-17 and 
-144 (Fig. S1b) slightly increased CRTC1, -2, and -3 mRNA levels (Fig. S1b) levels.
Inverse regulation of miRNA and Creb1/Crtc1-3 in allergic airway inflammation. As these results 
suggested that miRNA-17, -144, and -21 regulate Creb1 and its co-activators, we sought to verify this regulation 
during the development of OVA-induced AAI. In lung homogenates of OVA/OVA treated mice, the levels of all 
three candidate miRNAs significantly increased after the allergen challenge (day 72), but not during sensitization 
(day 29) (Fig. 3a). Additionally, the levels of miR-17, miR-144 and miR-21 significantly correlated with total 
cell counts in bronchoalveolar lavage (BAL), indicating an increased expression of the miRNAs upon increasing 
inflammation (Fig. 3b).
Creb1 mRNA was decreased in lung homogenate of those OVA/OVA treated mice on day 72 compared to 
PBS-treated controls (Fig. 4a). During OVA challenge the transcript levels of Creb1 and all three Crtcs decreased 
from day 29 to day 72; in control animals this was only seen for Crtc1 (Fig. 4a). The protein levels of Crtc1 and 
Crtc3 were assessed by western blotting and increased from day 29 to day 72 in control mice (Fig. S2a). This 
increase was significantly attenuated for Crtc3 following OVA challenge.
To further validate these findings in a model with more relevance for human asthma we used house dust mite 
(HDM) induced experimental asthma. Briefly, female 6–8 week old Balb/c were treated intranasally three times 
per week over five weeks with 20 μ g Dermatophagoides pteronyssinus extract (Nr. 218234; Greer, Lenoir, USA). 
Creb1 and Crtc1, 2 and 3 mRNA levels were significantly decreased in HDM-treated animals (Fig. 4b), and nega-
tively correlated with increased airway hyperreactivity (Fig. 4c). HDM-treatment also significantly reduced Crtc3, 
with a trend towards reduction in Creb1 protein levels (Fig. S2b).
The Creb1 transcriptional target Sec14l3 is decreased in murine AAI. As Creb1 and the Crtcs were 
altered in the both murine AAI models, we asked whether their down-regulation also negatively influences the 
transcription of Creb1 target genes. To this end, we searched an mRNA array previously performed (using lung 
homogenate collected on d72) of our OVA model31 (GEO database, ID: GSE6496 (http://www.ncbi.nlm.nih.gov/
geo) for down-regulated genes containing CRE-sites in OVA/OVA vs. PBS/OVA mice. Of 185 decreased genes, 35 
contained putative CRE-elements (Table S2). We selected Sec14-like 3 (Sec14l3) for further investigation as it had 
already been found to be decreased in allergic airway inflammation in rats32 and to be specifically expressed in 
murine airway ciliated cells33. Sec14l3 mRNA levels were decreased in lungs of OVA-animals (Fig. 5a). Similar to 
Creb1 and the Crtcs, Sec14l3 protein levels increased in PBS/OVA mice, but the increase was abolished in animals 
with OVA-induced allergic inflammation (Fig. 5b). Immunofluorescence staining demonstrated Sec14l3 expres-
sion in airway ciliated cells of healthy animals, with lower levels in OVA-induced AAI (Fig. 5c). PAS staining of 
Figure 3. miRNA regulation in murine allergic airway inflammation. (a) Expression analysis via qRT-PCR 
for miRNAs of lung homogenates of PBS/OVA and OVA/OVA mice (n = 5 mice per group), y-axis depicts 
dCp values (CpmiRNA-Cpreference miR) – higher dCp means lower expression (reversed scale), Mann-Whitney U, 
*p < 0.05; **p < 0.01 vs. PBS/OVA control. (b) Correlations of miRNA dCp values with total cell counts from 
bronchoalveolar lavage (BAL).
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matching lung sections showed a concomitant goblet cell metaplasia (Fig. 5c). These findings were corroborated 
in HDM-induced AAI (Figs 5d,e and S4). In the HDM model, Sec14l3 mRNA levels also significantly and nega-
tively correlated with increasing airway hyperreactivity and total cell counts in the BAL (Fig. 5f). This suggested 
that loss of Sec14l3 is associated with AAI, independent of the type of allergen.
IL13 induced goblet cell metaplasia in primary NHBE cells decreases SEC14L3 expression. In 
order to get further insight into the regulation of epithelial SEC14L3 in the context of allergic airway inflamma-
tion, we differentiated primary normal human bronchial epithelial (NHBE) cells (Lonza, Basel, Switzerland) at 
the air-liquid interface in PneumaCult™ -ALI medium (Stemcell Technologies; Köln, Germany) containing 1% 
penicillin/streptomycin at 5% CO2 and 37 °C. After 28 days, a pseudostratified epithelium was formed, contain-
ing goblet, club, ciliated and basal cells34. To induce early asthma-like changes in the bronchial epithelium, the 
cells were treated with 10 ng/mL of the potent Th2 cytokine IL13 (R&D Systems, Wiesbaden, Germany) from the 
basolateral side between d0 and d7 (Fig. 6a).
On day 0, SEC14L3 mRNA was undetectable, but levels increased markedly until day 28 (Fig. 6b). Of note, this 
increase closely correlated with mRNA expression of the transcription factor Forkhead box protein J1 (FOXJ1) 
which is associated with the development and function of ciliated cells35 (Fig. 6c).
Induction of goblet cell metaplasia was confirmed by a cross-section PAS staining of the transwell membranes 
(Fig. 7a) and Mucin 5A/C (MUC5AC) mRNA increase (Fig. 7b). The mRNA of CREB1 and its co-activator CRTCs 
decreased significantly after only 24 hours of IL13 treatment, but then increased over time (Fig. 7c). These find-
ings were largely translated to the protein level (Fig. 7d), although with more prolonged decreases. SEC14L3 and 
FOXJ1 transcript levels were significantly decreased upon IL13 treatment (with levels not detectable at 24 h), 
abolishing the increase observed during normal differentiation (Fig. 7e).
Overall, changes in the bronchial epithelium in response to Th2 stimuli seem to disturb 
CREB1/CRTC-mediated transcription of its putative target SEC14L3.
Figure 4. Down-regulation of Creb1/Crtc expression in murine allergic airway inflammation. Expression 
analysis via qRT-PCR for Creb1, Crtc1, Crtc2 and Crtc3 in (a) lung homogenates of PBS/OVA and OVA/OVA 
mice (5 mice per group), (b) lung homogenates of HDM-treated mice vs. PBS-treated controls (6 mice per 
group). (a,b) y-axis depicts dCp values (Cpgene-Cpreference gene) – higher dCp means lower expression (reversed 
scale). All mean ± SD, Mann-Whitney U, *p < 0.05; **p < 0.01 vs. respective controls. (c) Correlations of Creb1 
& Crtc1, Crtc2 and Crtc3 dCp values with airway hyperreactivity (Ahr) as depicted by resistance to 12.5 mg/ml 
methacholine.
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Discussion
Several studies have shown that modulation of single miRNAs such as miR-2111,36, let-7d13 and miR-1458 inhib-
its or ameliorates the development of allergic airway inflammation in mice. In this study, rather than study-
ing single miRNAs during asthma development, we used profiles of dysregulated miRNA as a tool to identify 
novel, regulatory gene networks of relevance for the pathogenesis of asthma that might be overlooked by mRNA 
array based studies. We identified down-regulation of Creb1/Crtc-mediated transcription and its putative target 
Sec14l3 in two murine experimental models, independent from the type of allergen. In primary NHBE cells, we 
demonstrated that soon after IL13 exposure CREB1 and CRTC levels were decreased. Th2 stimulus also decreased 
SEC14L3 and FOXJ1 expression, which was associated with goblet cell metaplasia.
Altered expression of miRNAs have been observed in bronchial biopsies of patients with asthma6,7. Previous 
researchers have proposed the miR-34/449 family6 and miR-146a7 to regulate epithelial changes in human 
asthma, influenced by cytokine stimulation in human bronchial epithelial cells. However, neither miR-146a nor 
the 34/449 family were significantly altered in our array. This might be explained by the fact that the prior stud-
ies investigated miRNAs in isolated human bronchial epithelial cells, whereas we conducted the miRNA profile 
analysis in murine lung homogenate.
Up-regulation of miR-21 with repression of IL-12p35 has previously been demonstrated in three different 
animal models of allergic airway inflammation11, and recently also in severe steroid-insensitive asthma36. The 
Figure 5. Sec14l3 in murine allergic airway inflammation. (a) qRT-PCR and (b) Western blot and 
densitometrical analysis of OVA-treated animals, mean ± SD, (n = 5 mice/ group). The blot was cropped to 
improve clarity – full-length blots are provided in Supplemental Fig. S3 (c) Representative lung sections: Sec14l3 
(red) vs. DAPI (blue), (left) or PAS (right). Arrowheads: Sec14l3 + cells (left) and goblet cells (right) (4 mice/
group). HDM-treated mice (n = 6 mice/group), mean ± SD (d) qRT-PCR. (a,d) y-axis depicts dCp values 
(Cpgene-Cpreference gene) – higher dCp means lower expression (reversed scale) (e) densitometrical analysis of 
Western blot. *p < 0.05; **p < 0.01 vs. PBS. (f) Correlations of Sec14l3 mRNA (dCp values) with total cell counts 
in BAL and airway hyperreactivity (Ahr) as depicted by resistance to 12.5 mg/ml methacholine.
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miR17-92 family is broadly expressed from earliest development to adulthood and plays a central role in lung 
development37. So far, dysregulation of miR-17 has been mainly investigated in the context of cancer38,39, but 
has also been proposed to regulate IL-10 in regulatory T cells40. The transcription of IL10 has also been shown 
to be regulated by Creb and Crtc3 in regulatory macrophages41. Thus, the miRNA-mediated down-regulation 
of Creb1 and Crtc3 in AAI, combined with the up-regulation of miR-17, could influence the secretion of the 
anti-inflammatory cytokine IL10 and could therefore have a beneficial impact on airway inflammation. Recently, 
miR-17/20 has also been shown to regulate pulmonary artery smooth muscle cell proliferation via targeting prolyl 
hydroxylase 2, leading to induction of hypoxia-inducible factor (HIF) 1α 42. Of note, HIF1α deletion in mice has 
been shown to ameliorate OVA-induced asthma with lower eosinophil infiltrations, reduced goblet cell hyper-
plasia and lower Th2 cytokine levels. Thus, it is intriguing to speculate that increased miR-17 levels in our model 
might induce HIF1α levels, contributing to allergic airway inflammation.
To our knowledge the involvement of miR-144 has not been proposed in allergic airway inflammation so far. 
This miRNA is abundantly expressed in red blood cells43, but has recently been investigated in lung cancer biol-
ogy44,45, showing a functional expression in lung cells.
It should be noted that in our series of experiments we only sought to use miRNA profiles to identify dysregu-
lated asthma profiles. Further work would be needed to provide functional proof that these pathways are involved 
in asthma pathogenesis, and indeed this would be a most intriguing area for future investigation.
In our acute murine models Creb1 and Crtc down-regulation was detected directly after allergen challenge 
and further, human CREB1/CRTCs were significantly down-regulated in primary NHBE cells early after IL13 
treatment, but returned to normal after 7 days. Therefore, we speculate that an initial but transient dysregulation 
of CREB1 and CRTC-mediated transcription is sufficient to induce lasting changes of downstream targets in 
asthma (either directly or indirectly).
Our findings run partly counter to two reports, one showing an increase of pulmonary phosphorylated (p)
CREB in adult steroid-resistant or untreated asthma25, and the other reporting an increase of total CREB in 
peripheral blood of patients with recurrent wheeze46. However, in a novel analysis of published gene expression 
data (DEGAS = DysrEgulated Gene set Analysis via Subnetworks) with the aim to identify subnetworks and 
dysregulated pathways in diseases, CREB1 was listed as down-regulated in airway epithelial cells of patients with 
asthma, confirming our finding from primary NHBE cells47,48. Further, CREB1 binding activity negatively corre-
lated with recurrent airway obstruction in horses, which have many similarities with human asthma26. Similar to 
our findings with IL13, the Th2-associated chemokine CCL17 has been shown to down-regulate CREB1 in vitro24. 
Another study has proposed CREB1 to be influenced by IL17, a cytokine that is implicated in the pathogenesis of 
severe asthma49. Thus, the role of CREB1 in asthma is not yet clear and requires further investigation.
Crtc proteins have so far been mainly described in the context of regulation of metabolism. With the exception 
of one study that suggested Crtc3 promotes IL10 synthesis41, reports on Crtcs in immune regulation are scarce50. 
The involvement of Crtcs in asthma or any other lung disease has to our knowledge not been investigated so far.
The lipid transporter Sec14l3 has been proposed as being important for the maintenance and homeostasis 
of rat airway epithelial cells32. In our study, Sec14l3 was strongly down-regulated in ciliated cells of animals with 
experimental AAI. We do not have direct proof that Creb1 binds to the promoter of Sec14l3 as the latter gene is 
not expressed in lung cell lines, impeding siRNA studies. Nonetheless, the CRE-element in the Sec14l3 promoter 
is evolutionary highly conserved, suggesting functional relevance. Little is known regarding functions of Sec14l3, 
which is highly induced around birth in lung tissue51. In mammalians more than 20 Sec14 family members have 
been described, carrying highly conserved lipid-binding domains52. Sec14l3 has been specifically implicated in 
the intracellular transport of α -tocopherol53 and has been proposed as sensor of liposomal lipid-packing defects 
in the lung51. Human SEC14L3 has been found to be decreased in bronchial and nasal epithelium of smokers54 
and during human rhinovirus infection55. In the present work, loss of SEC14L3 expression in ciliated cells in 
Figure 6. SEC14L3 increases during NHBE differentiation and correlates with FoxJ1. (a) Treatment scheme 
of differentiation of primary normal human bronchial epithelial cells (NHBE) into a pseudostratified epithelium 
at the air-liquid interface. (b) qRT-PCR for SEC14L3 and FOXJ1 from day 7 to day28 of differentiation 
(n = 4 independent experiments). y-axis depicts dCp values (Cpgene-Cpreference gene) – higher dCp means lower 
expression (reversed scale). (c) Linear correlation of dCp values of SEC14L3 and FOXJ1 (n = 4 independent 
experiments).
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mouse lungs and human primary bronchial cell cultures correlated with goblet cell metaplasia. Thus, the SEC14L3 
expression profile could mirror cellular changes in the epithelium.
In summary, we have identified a dysregulation of Creb1, the Crtcs (1–3) and their transcriptional target 
Sec14l3 in early stages of asthma pathogenesis. Thus, we suggest that miRNA profiles can be used as tool for pri-
oritization of disease-relevant pathways.
Materials and Methods
Animals. Female Balb/c mice were obtained from Charles River (Sulzfeld, Germany) and housed in individ-
ually ventilated cages. A standard pellet diet and water were provided ad libitum. The study was conducted under 
the German federal guidelines for the use and care of laboratory animals and was approved by the Government 
of the District of Upper Bavaria.
Ovalbumin-induced allergic airway inflammation. Female 6 to 8 weeks old Balb/c mice were intra-
peritoneally (i.p.) sensitized with 1 μ g ovalbumin (OVA) (Sigma Aldrich, St. Louis, USA) (or phosphate buffered 
saline (PBS) for controls) in alum, followed by two aerosol challenges with 1% OVA for 20 min (Fig. S6a) as pre-
viously described56. Mice were sacrificed on day 29 or 72 (Fig. S6a). The ability of the model to generate moderate 
allergic airway inflammation was verified by high levels of OVA-specific serum IgE and IgG1 (Fig. S6b), elevated 
numbers of inflammatory cells in bronchoalveolar lavage fluid (BALF) (Fig. S6c,d), elevated titers of CCL17 in 
BALF (Fig. S6e), and goblet cell metaplasia in the lungs (Fig. S6f).
RNA extraction and quality analysis. Total RNA (including small RNAs) was isolated from homog-
enized lung tissue or cell culture using the miRNeasy Mini Kit according to the manufacturer’s instructions 
(Qiagen, Venlo, The Netherlands). Concentrations were determined using a NanoDrop® ND-1000 spectropho-
tometer (NanoDrop Technologies, Erlangen, Germany). Quality was assessed by gel electrophoresis and by using 
the Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, USA).
Figure 7. IL13 treatment of NHBE cells reduces CREB1 and SEC14l3. (a) PAS staining of transwell 
membranes. (b) qRT-PCR for MUC5AC. (c) qRT-PCR for CREB1 and CRTC1-3. (d) Representative western 
blot and densitometrical analysis. The blot was cropped to improve clarity – full-length blots are provided in 
Supplemental Fig. S5 (e) qRT-PCR for SEC14L3 and FOXJ1. All graphs depict fold change vs. control. n.d. = not 
detectable. All n = 4, Mann-Whitney U, *p < 0.05 vs. untreated control.
www.nature.com/scientificreports/
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Locked nucleic acid miRNA microarray. Hy3-/Hy-5 labelled RNA (miRCURY LNA microRNA Array 
Power Labeling Kit, Exiqon, Vedbaek, Germany) was manually hybridized on miRNA microarrays (miRCURYTM 
LNA microRNA Array v10, Exiqon), which comprised 580 murine miRNAs (miRBase release 10.0). Slides 
were scanned by a GenePix 4000A Microarray Scanner (Axon Instruments, Foster City, USA) and analyzed by 
GenePix® Pro Software (Axon Instruments). Differential expression of miRNAs was identified using a linear 
model approach (limma, Bioconductor analysis suite57). After background subtraction, non-positive spots were 
removed and the remaining signal intensity values were normalized to a small control RNA (RNU6B) (Life tech-
nologies, Carlsbad, USA). P-values were adjusted to multiple testing by Bonferroni correction.
Low density array. For validation of the microarray data, TaqMan® Array Rodent MicroRNA Cards 
(Applied Biosystems, Life Technologies, Carlsbad, USA) were performed according to the manufacturer’s pro-
tocol with an input of 350 ng total RNA per array card and pre-amplification procedure. In total 518 murine 
miRNAs were measured. The array version 2.0 (miRBase v.10.0) was run on an ABI PRISM® 7900HT real-time 
PCR machine (Applied Biosystems, Carlsbad, USA) and analyzed by SDS-software (SDS v2.2) via a comparative 
cycle threshold method (∆ ∆ Ct)58.
Microarray statistics. Statistical analysis was carried out with the data analysis and statistics language R 
(R Foundation for Statistical Computing) using the Bioconductor suite for bioinformatics59, specifically the 
limma package57,60 which fits a linear model for each gene and computes a moderated t-statistic and its P value61. 
Background correction was done using the normexp method by Ritchie et al.62. Within-array normalization was 
carried out by robust spline normalization of the log R/G ratio and scaling was used for between-array normali-
zation. P values were corrected for multiple testing by the method of Benjamini and Hochberg63.
Quantitative real-time PCR (qRT-PCR). Expression of single miRNAs was evaluated using 
TaqMan-based specific real-time PCR (Applied Biosystems, Carlsbad, CA, USA) following the manufacturer’s 
instructions and normalized to small control RNA sno-234 (Life technologies) for murine tissue and murine 
cell lines and RNU-6B (Life technologies)for human cells lines and nasal brushings. mRNA was converted to 
cDNA with the QuantiTect Rev. Transcription Kit (Qiagen, Venlo, The Netherlands). PCRs were performed on 
the LightCycler 480 platform (Roche, Mannheim, Germany) using LightCycler 480 SYBR Green I Mastermix 
or for miRNAs TaqMan® Universal PCR Master Mix (Invitrogen, Carlsbad, USA). Expression differences were 
calculated based on the ∆ ∆ Ct method using HPRT as reference gene58. Specific primer sequences for CREB1, 
CRTC1-3, SEC14L3, FOXJ1 and MUC5AC are provided in the Table S3.
In silico target predictions. A strict “full consensus” approach using five different prediction algorithms 
was applied: miRanda: (http://www.microrna.org/microrna/getDownloads.do); PicTar (www.pictar.org); PITA: 
(genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html), Targetspy (http://webclu.bio.wzw.tum.de/targetspy/
index.php?down= true); Target-ScanS: (genes.mit.edu/targetscan). Only fully-consensus predicted targets were 
considered for initial target prioritization. We therefore included a second step in which we critically reviewed 
miRNAs that had been excluded from the full-consensus algorithm approach, but that targeted Crtc1, Crtc2 or 
Crtc3. Thus, miRNAs that only met two of the algorithms (miRanda and PITA), and that are known to be bio-
logically relevant and highly deregulated, were also included, providing their binding was subsequently verified 
in vitro. For a complete list of predicted miRNA binding sites in the Crtc1, Crtc2 and Crtc3 genes see Table S1”.
Cell culture. Murine lung epithelial cells (MLE-12) and human bronchial epithelial cells (16-HBE14o−)64 
were cultured in MEM medium supplemented with 10% FCS at 37 °C and 5% CO2 without antibiotics under 
standard conditions.
Luciferase reporter assay. The complete Creb1 3′ untranslated region (UTR) was amplified from mouse 
genomic DNA (see Table S3 for primer sequences) and cloned into psiCHECK-2 vector (Promega, Madison, 
USA). Fifty ng of the vector construct were transfected into 16-HBE14o− cells together with the precursor miR-
NAs of interest or a negative control miRNA. After 72 h, cells were lysed (200 mM Tris-HCl, 0.1% Triton in 500 ml 
H2O, pH 7.4) and Renilla and firefly luciferase activities were measured (Wallac 1420 Multilabel counter, Perkin 
Elmer, Waltham, USA) after addition of the respective substrates. Renilla luciferase activity was normalized to 
firefly luciferase activity.
Transfection assays. Transfection experiments were conducted with Lipofectamine 2000 (Invitrogen, 
Carlsbad, USA) in 12-well plates following manufacturer’s instructions. Ambion® Pre-miR Precursors (for miR-
17 and miR-144), miRvana miRNA mimics (for miR-21) (Ambion, Austin, USA) or antimiRs (miR-17 and -144) 
(Ambion, Austin, USA) were transfected in duplicates to a final miRNA concentration of 20 nM per well in a 
murine lung epithelial cell line (MLE-12) or a human bronchial epithelial cell line (16-HBE14o−)64. Analyses were 
done 72 h after transfection for Pre-miRNA or 24 h for antimiR transfection.
Western blotting and densitometry. Lung tissue or cells from culture were homogenized in RIPA 
buffer containing 10 mM NaF, 1 mM Na3VO4, 1 mM DTT and protease inhibitor and sonicated for 10 sec to 
disrupt cellular structures. Protein concentrations were measured using Pierce BCA protein assay kit (Thermo 
Fischer Scientific, Waltham, USA) following the manufacturer’s protocol. 20 μ g protein per well were sepa-
rated by SDS-Polyacrylamid-gel-electrophoresis and transferred to PVDF membranes by wet blotting (BioRad, 
Hercules, USA). Membranes were incubated under constant agitation over night at 4 °C with antibodies against 
Creb1, Crtc1, Crtc3, Sec14l3 (Abcam, Cambridge, USA) or Gapdh antibody as loading control (all Cell signalling 
Technology, Danvers, USA) (all 1:1000 in 5% BSA in TBS-T) and for 1.5 h at room temperature with secondary 
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HRP-conjugated goat anti-rabbit IgG antibody (BioRad, Hercules, USA) (1:40000, 5% BSA in TBS-T). ECL, 
Dura-ECL and Femto-ECL (Thermo Fischer Scientific, Waltham, USA) were used for detection via Chemidoc 
XRS+ Molecular Imager (BioRad, Hercules, USA). For reprobing, membranes were stripped in Restore Plus 
Stripping buffer (Thermo Fischer Scientific, Waltham, USA) according to the manufacturer’s recommendations. 
Quantification of band intensities was performed with the Image Lab software v4.01 (BioRad, Hercules, USA).
House dust mite induced allergic airway inflammation. For house dust mite (HDM) induced AAI, 
mice were treated intranasally 3 times per week over 5 weeks with 20 μ g Dermatophagoides pteronyssinus extract 
(Nr. 218234; Greer, Lenoir, USA) in 30 μ L PBS or PBS (Fig. S7a). HDM-induced allergic airway inflammation was 
validated by BALF cell counts (Fig. S7b), differential cell counts (Fig. S7c), increased airway hyper-reactivity in 
response to metacholine (Fig. S7d), and lung inflammatory cell infiltration (Fig. S7e).
Lung function. Animals were i.p. anesthetized with ketamine (140 mg/kg) and xylazine (7 mg/kg), trache-
ostomized, intubated (18G tube), placed on a warming plate and ventilated with a tidal volume of 10 mL/kg at 
a frequency of 150 breaths/minute and a positive end-expiratory pressure of 2 cm H2O on a Buxco R/C system. 
To assess airway hyperreactivity, the mice were challenged with metacholine in physiological saline generated 
with an in-line nebulizer and administered directly with increasing concentrations (0, 6.25, 12.5 mg/mL) for 
20 seconds. The highest values of respiratory system resistance were recorded continuously for 2 min after each 
metacholine dose, the average was calculated and plotted against metacholine concentration.
Creb1 target gene search. The palindromic cAMP responsive elements (CRE)-elements in the promoter 
region of potential Creb1 targets (5′ -TGACGTCA-3′ ) were identified by using “MatInspector Release professional 
8.0.5, March 2011 (Database version: ElDorado 08–2011; MatInspector library: Matrix Family Library Version 
8.4” (June 2011), Table S2).
Lung histology and Immunofluorescence staining. Goblet cell hyperplasia was assessed by a peri-
odic acid Schiff stain (PAS) in formalin-fixed, paraffin-embedded lung tissue sections. Sec14l3 expression was 
determined by immunofluorescence using a specific rabbit anti-rat Sec14l3 antibody (Abcam, Cambridge, MA, 
USA) (1:200) and Alexa Fluor 568 goat anti-rabbit IgG (H+ L) (Life technologies, Carlsbad, USA) (1:250). Nuclei 
were co-stained with DAPI (1:2500, 0.5 μ g/mL). Specific binding of murine Sec14l3 was verified by western blot 
beforehand.
Primary normal human bronchial epithelial cell differentiation and IL13 treatment. Primary 
human bronchial epithelial (NHBE) cells from different healthy donors (Lonza; Wokingham, UK) were culti-
vated in bronchial epithelial cell growth medium (BEGM) (Lonza; Wokingham, UK) as described previously34. 
NHBE cells were differentiated up to 28 days at the air-liquid interface (ALI) using PneumaCult™ -ALI medium 
(Stemcell Technologies; Köln, Germany) containing 1% penicillin/streptomycin. For induction of goblet cell 
metaplasia, NHBE cells were exposed to 10 ng/mL IL13 (R&D systems, Wiesbaden, Germany) between day 0 and 
day 7 of ALI-culture from the basolateral side of the transwell. IL13 treatment was renewed every 2–3 days with 
simultaneous changes of the growth medium. For cross-section histology, the membranes were fixed with 4% 
paraformaldehyde (PFA) and embedded in 2% agarose in Hank’s balanced salt solution (HBSS) prior to paraffin 
embedding.
Statistics. Unless stated otherwise, the non-parametric Mann-Whitney U test was applied for animal experi-
ments and cell cultures with n ≥ 4, and ANOVA plus Bonferroni for lung function measurements with *p ≤ 0.05, 
**p ≤ 0.01; ***p ≤ 0.001. Data are presented as mean ± SD (GraphPad Prism 5 software; La Jolla, CA, USA).
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